E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
tuberculosis infection in patients under the age of 6 |
Infección tuberculosa en pacientes menores de 6 años |
|
E.1.1.1 | Medical condition in easily understood language |
tuberculosis infection in patients under the age of 6 |
Infección tuberculosa en pacientes menores de 6 años |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Bacterial Infections and Mycoses [C01] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Isoniazid maximum concentration description in serum of patients under the age of 6 in treatment with a unique oral daily dose of study drug 10mg/Kg for primary o secundary chemoprophylaxis of latent tuberculosis infection or tuberculosis disease treatment. |
Describir la concentración máxima de isoniazida en suero en una muestra de pacientes menores de 6 años tratados con el fármaco en estudio a una dosis única oral diaria de 10 mg por kg de peso para la quimioprofilaxis primaria o secundaria de la infección tuberculosa latente o el tratamiento de la enfermedad tuberculosa. |
|
E.2.2 | Secondary objectives of the trial |
- Describe other pharmacokinetic parameters (are under the curve, time to the maximum concentration), after the isoniazid administration in a unique oral daily dose of 10mg/kg in the study population and the equivalence between the two groups of patients: baby from 1 month to 2 years; and preschoolers, from 2 to 6 years of life. - Study the influence of other factors in the pharmacokinetics parameters studied: gender, nutritional state, treatment indication (primary or secundary chemoprophylaxis of the latent tuberculosis infection or tuberculosis disease treatment), acetylator NAT2 genotype and coadministration of other tuberculostatic drugs. - Treatment security. |
- Describir otros parámetros farmacocinéticos (área bajo la curva, tiempo a la concentración máxima), tras la administración de isoniazida en una dosis única oral diaria de 10 mg por kg de peso en la población en estudio, y su equivalencia entre los dos grupos de pacientes: lactantes, de 1 mes a 2 años de vida; y prescolares, de 2 a 6 años de vida. - Estudiar la influencia de otros factores en los parámetros farmacocinéticos estudiados: género, estado nutricional, indicación de tratamiento (quimioprofilaxis primaria o secundaria de la infección tuberculosa latente o tratamiento de la enfermedad tuberculosa), genotipo acetilador NAT2 y co-administración de otros fármacos tuberculostáticos. - Seguridad del tratamiento. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Patients between > or = 29 days and < or = 6 years old. - Patients who require primary or secundary chemoprophylaxis, or treatment for the tuberculosis infection with isoniazid in monotherapy or together other anti-tuberculosis drugs. - Informed consent signed by parents and tutors. |
- Pacientes entre > o = 29 días y < o = 6 años de vida. - Pacientes que precisen quimioprofilaxis primaria o secundaria, o tratamiento para la infección tuberculosa con isoniazida, en monoterapia o junto a otros fármacos anti-tuberculosos. - Formulario de consentimiento informado firmado por los padres o tutores. |
|
E.4 | Principal exclusion criteria |
- Any infection disease, hepatic or renal of base susceptible to alter the isoniazid metabolism (i.e. VIH infection or hepatotropos virus). - Treatment necesity with other drugs liable to modify the isoniazid metabolism (i.e. antiepileptic, antiretroviral, etc.). - Study basal hepatic function alteration, defined with a elevation in the alanine aminotransferases levels two or three times the normality higher level, it is 40 UI/L per 2: values > or 80UI/L. |
- Cualquier enfermedad infecciosa, hepática o renal de base susceptible de alterar el metabolismo de la isoniazida (ej. infección por VIH o virus hepatotropos). - Necesidad de tratamiento con otros fármacos susceptibles de alterar el metabolismo de la isoniazida (ej. antiepilépticos, antirretrovirales, etc.). - Alteración de la función hepática en el estudio basal, definida por una elevación de los niveles de alanino aminotransferasa (ALT) dos o más veces el valor superior de la normalidad, o sea, 40 UI/L por 2: valores > o = 80 UI/L. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Maximum concentration (Cmax) in serum of isoniazid (quantitative variable, in mg/L) |
Concentración máxima (Cmax) en suero de isoniazida (variable cuantitativa, en mg/L). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Patients in monoterapy:1 or 2 hours post-dosis, 3 or 4 hours post-dose, 6 or 8 hours post-dosis. In combined treatment with other drugs anti-tuberculose : Pre-dose, 1 or 2 hours post-dose, 3 or 4 hours post-dose, 6 or 8 hours post-dose and 10 or 12 hours post-dose |
Pacientes en monoterapia: 1 o 2 horas post-dosis, 3 o 4 horas post-dosis, 6 o 8 horas post-dosis. En tratamiento combinado con otros fármacos anti-tuberculosos: Pre-dosis, 1 o 2 horas post-dosis, 3 o 4 horas post-dosis, 6 o 8 horas post-dosis y 10 o 12 horas post-dosis. |
|
E.5.2 | Secondary end point(s) |
- Time to the maximum concentration in serum of isoniazid (quantitative variable, in hours). - Minimum concentration in serum of isoniazid (quantitative variable, in mg/L). - Area under the curve of isoniazid concentration in serum (quantitative variable, in mg h/L). From time 0 to 6h (AUC6) and time from 0 to 24h (AUC24) in a posological interval. - Plasmatic clearance of isoniazid (quantitative variable, in L/h) - Apparent distribution volume of isoniazid ( quantitative variable, in liters). - Acetylator genotype (qualitative variable): quick homozygote acetylator, slow homozygote acetylator, or intermediate acetylator. - In patients with tuberculosis disease: disease type (intrathoracic or extratoracic; dichotomic variable) and concomitant treatments with other tuberculostatic drugs (yes/no; dichotomic variable). - Malnutrition (yes/no, dichotomic variable). Defined with weight and/or body mass index lower than -2DS according to the Spanish standar. - Gender, gestational state and weight in the moment of birth, indication about the treatment with isoniazid (primary or secondary chemoprophylaxis of ITL, or tuberculosis disease treatment); age, weight and total daily dose of isoniazid and basal levels of alanine aminotransferase (ALT-UI/mL) to the initial treatment indication with isoniazid; adherence and adverse events to the treatment with isoniazid. |
- Tiempo a la concentración máxima (tmax) en suero de isoniazida (variable cuantitativa, en horas). - Concentración mínima (Cmin) en suero de isoniazida (variable cuantitativa, en mg/L). - Área bajo la curva (AUC) de concentración de la isoniazida en suero (variable cuantitativa, en mg h/L). De tiempo 0 a 6h (AUC6) y de tiempo 0 a 24h (AUC24) en un intervalo posológico. - Aclaramiento plasmático (CL) de isoniazida (variable cuantitativa, en L/h). - Volumen aparente de distribución (Vd) de isoniazida (variable cuantitativa, en litros). - Genotipo acetilador (variable cualitativa): acetilador rápido homozígoto (RR), acetilador lento homozígoto (LL), o acetilador intermedio (RL). - En los pacientes con enfermedad tuberculosa: tipo de enfermedad (intratorácica o extratorácica; variable dicotómica) y tratamiento concomitante con otros fármacos tuberculostáticos (sí/no; variable dicotómica). - Desnutrición (sí/no, variable dicotómica). Definida por un peso y/o índice de masa corporal inferior a -2 DS de acuerdo a los estándares españoles. - Género, estado gestacional y peso al nacimiento, indicación de tratamiento con isoniazida (quimioprofilaxis primaria o secundaria de la ITL, o tratamiento de la enfermedad tuberculosa); edad, peso y dosis total diaria de isoniazida, y niveles basales de alanina aminotransferasa (ALT - UI/mL) a la indicación inicial del tratamiento con isoniazida; adherencia y efectos adversos al tratamiento con isoniazida. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Patients in monotherapy: 1 or 2 hours post-dose, 3 or 4 hours post-dose, 6 or 8 hours post-dose. In combinate treatment with other drugs anti-TB: Pre-dose, 1 or 2 hours post-dose,3 or 4 hours post-dose, 6 or 8 hours post-dose and 10 or 12 hours post-dose. |
Pacientes en monoterapia: 1 o 2 horas post-dosis, 3 o 4 horas post-dosis, 6 o 8 horas post-dosis. En tratamiento combinado con otros fármacos anti-TB: Pre-dosis, 1 o 2 horas post-dosis, 3 o 4 horas post-dosis, 6 o 8 horas post-dosis y 10 o 12 horas post-dosis. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |